Skip to content
Artwork for The GMP Insider
ScienceLife Sciences

The GMP Insider

Tushar Arora

GMP Insider is your go-to podcast for practical insights into pharmaceutical quality, Good Manufacturing Practices (GMP), and regulatory compliance.

Designed for quality professionals, manufacturing teams, and pharma leaders, this show breaks down complex regulations into clear, real-world guidance. Each episode explores topics like audits, CAPA, data integrity, quality systems, validation, and global regulatory expectations — all with a focus on protecting patients and building strong quality cultures.

Whether you work in Quality Assurance, Quality Control, Manufacturing, or Regulatory Affairs, GMP Insider helps you stay compliant, confident, and ahead in an ever-evolving pharmaceutical industry.

New episodes deliver:
• GMP best practices
• Audit readiness strategies
• Real compliance case studies
• Industry trends and updates
• Expert tips from quality professionals

From batch to patient — quality is everything.

Play
  • 46 episodes
  • Avg 17 min
  • English
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • Wednesday · 15 min

    Cleaning Validation: Worst-Case Approach, PDE and MACO Limits

    Cleaning validation fails in places nobody looked: the product nobody chose, the limit nobody calculated, the swab nobody recovered. Marcus and Priya work through the modern approach — worst-case product selection argued on paper, health-based PDE limits replacing inherited rules of thumb, the MACO carryover calculation step by step, and the sampling, recovery, and hold-time science that makes the numbers defensible. • What cleaning validation must prove: the API is not the whole residue story — degradants, detergents, and bioburden included• The worst-case product: a scientific argument, not a vote — solubility, potency, cleanability, and the bracketing logic behind it• From dose rules to PDE: why the old one-thousandth-of-dose and ten-parts-per-million rules over-clean the easy and under-clean the potent• MACO walked through: previous product PDE, next batch size, maximum daily intake — and running it per product pair, not with one number for the building• Surface limits, the swab caveat, and recovery studies: why recovery below fifty percent suggests the method cannot find the residue• Dirty and clean hold times, campaign sizing, and verification versus validation in multipurpose facilities New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • Monday · 14 min

    Environmental Monitoring: Alert vs Action Limits & Trending

    An environmental monitoring programme can collect data for a year and still know nothing — thousands of results, beautifully filed, never trended, never questioned. Marcus and Priya lay out EM done properly: alert limits built from your own baseline, trending by location, organism and operator, excursion investigations that separate the batch decision from the root-cause hunt, and the findings inspectors write when the data existed but the thinking didn't. • What EM is actually for: the evidence system for state of control inside the contamination control strategy• Alert vs action limits: statistical tripwires from your own baseline vs the boundary of the qualified state — and why copied limits are decoration• Trending where the truth lives: drift before spikes, control charts, review cadence, and named ownership• Organism identification: the species is the source investigation's first clue — skin flora, spore formers, water organisms• On the filling line: monitor the act, the actor, and the moment — interventions, personnel, and continuous grade A particle data• Excursions: batch impact decided on the totality, patterns of alerts treated as excursions, and repeat signatures escalated to CAPA New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • #10
    November 11 · 12 min

    ICH Q9(R1) Quality Risk Management: What's Actually New

    Most quality risk assessments fail in the first ten minutes, when someone picks a score out of the air and the room nods. Marcus and Priya break down what the ICH Q9(R1) revision actually changed: formality that follows risk, subjectivity named and managed as a bias problem, product availability as a new risk lens, and risk review that turns assessments into living records instead of souvenirs. • What Q9(R1) changed — and what it deliberately left alone: the core model, the tools annex, and the two founding principles• Formality: effort as a deliberate, documented decision, proportionate to risk — and why one template for everything is always wrong• Subjectivity: threshold-hugging scores, false consensus, and the structural fixes — anchored scales, independent scoring, recorded dissent• Scoring discipline: severity is not negotiable, acceptance criteria are set before scoring, and risk acceptance belongs to quality leadership• Product availability: a planning input for dual sourcing and escalation — never permission to release failing product• Risk review: owners, review triggers, and letting deviations and changes reopen assessments automatically New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • November 9 · 15 min

    Change Control Management: What Gets Companies in Trouble

    The most dangerous change in a GMP plant is not the big capital project everyone debates for a year — it is the small one nobody logged, because someone called it like for like. Marcus and Priya walk through change control management: what the system is actually for, the invisible changes that escape it, where impact and risk assessment do the real work, the timing failures inspectors cite, honest rules for emergency and temporary changes, and how to keep control without freezing the plant. • What change control actually is: 21 CFR 211.100, EU GMP, and ICH Q10 — and why the validated, registered state is the thing being protected• The invisible changes: like-for-like claims, temporary changes that never leave, software and spreadsheet changes, supplier notifications, and "editorial" edits• Assessment, where the real work is: cross-functional impact, the regulatory filing question, and risk assessment under ICH Q9• Timing failures: implementation before approval, training after the effective date, and the open tail of never-closed changes• Emergency and temporary changes: a faster door into the same system, expiry dates, owners, and end states• ICH Q12: established conditions and post-approval change management protocols — less theatre, more precision• What good looks like: a change log leaders test against floor reality, post-implementation effectiveness review, and change metrics in front of leadership New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • #2
    November 4 · 15 min

    Contamination Control Strategy (CCS) Under EU GMP Annex 1

    Most contamination control strategies fail on page one — not because anything in them is wrong, but because everything in them is copied from somewhere else. Marcus and Priya break down the CCS under EU GMP Annex 1: what it actually has to contain, how facility design, people, sterilisation, media fills, monitoring, and disinfection connect into one risk-based argument, the five failure patterns inspectors find again and again, and how to keep the strategy alive instead of letting it become a static binder. • What a CCS is under Annex 1 — planned controls for microorganisms, particles, and pyrogens, built on ICH Q9 risk management• Start with sources, not solutions: people, materials, air, utilities, and the process itself — prevention, detection, and response for each• First air: what it is, how interventions break it, and why design and training must protect it• People, gowning, and behaviour: qualification, monitoring, and what a bad trend must trigger• Process controls: sterilisation, PUPSIT, validated material transfer, and the media fill as the strategy's exam• Monitoring and disinfection as the feedback loop: trending, alert vs action limits, and disinfectant efficacy against site flora• The five failures inspectors actually find: template strategies, static documents, missing interactions, monitoring divorced from action, and rationale gaps• Keeping the strategy alive: event-based review triggers, a named owner, and sterility metrics in front of leadership New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • #7
    November 2 · 14 min

    Deviation Investigation & Root Cause Analysis: 5 Whys Done Right

    Most deviation investigations fail not because teams pick the wrong tool, but because they stop asking why the moment the answer becomes uncomfortable — usually at "human error" and a retraining record. Marcus and Priya walk through a real investigation: containment and timeline reconstruction in the first hours, the 5 Whys worked step by step on evidence, where the tool breaks, the fishbone breadth check, and how root cause should dictate a CAPA with an effectiveness check that can actually fail. • What a deviation is under 21 CFR 211.192 — and why investigation depth must match risk• The first hours: containment first, then timeline reconstruction from records, not memory• The 5 Whys done right: a precise problem statement, verified answers, and the system-level stopping rule• Where the 5 Whys breaks: single-lane tunnels, opinion chains, leading questions, and stopping at human error• Why human error is a starting point for questions, never a root cause• Checking the chain: fishbone categories, evidence tests, and documenting causes ruled out• From root cause to CAPA that works: extent of condition and a countable effectiveness criterion• What good investigators do differently — and why investigation quality is a leadership metric New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • October 28 · 15 min

    How to Respond to an FDA 483 (and Warning Letter) in 15 Working Days

    The inspection is over — and the second half of it has just started. Your written response to a Form FDA 483 is due within 15 working days, and FDA weighs it before deciding whether the matter ends there or escalates to a Warning Letter. Marcus and Priya lay out the full 15-day playbook: what a 483 is and is not, day-one triage and ownership, extent-of-condition review, root cause and CAPA discipline, evidence and timelines, the cold-read challenge review, and the five failures that sink responses again and again. • What a Form FDA 483 is — and is not: inspectional observations, not a final agency determination• The 15-working-day clock: when it starts, and why a late response can arrive after the decision• Days 1–2: one response owner, every observation logged verbatim, containment and extent-of-condition• Days 3–7: real root cause, and separating correction, corrective action, preventive action, and effectiveness checks• Days 8–15: how to structure and write the response, tone, disagreement with evidence, and the cold-read review• Warning Letters: same discipline, higher stakes — responding to the pattern, not just the paragraphs• The five failures that sink responses: narrow fixes, human-error shortcuts, promise piles, defensive tone, missed commitments New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • October 26 · 15 min

    FDA Inspection Readiness 2026: The New Cross-System Inspection Model

    FDA doesn't inspect your quality systems in silos anymore. The new inspection model is hypothesis-driven: the investigator pulls one thread — a complaint, a repeat deviation — through CAPA, risk management, and design as a single connected system, and watches whether your story holds. Marcus and Priya break down what changed in 2026, why training records and binders no longer equal readiness, the inspection playbook from war room to escorts, and the daily habits that make a site genuinely ready. • The 2026 shift: from subsystem inspections to hypothesis-driven, cross-system inspections• How the new inspection actually works — following one thread across the whole quality system• Why readiness is a daily habit, not a pre-inspection scramble• The inspection playbook: war room, back room, document retrieval, SME selection, escort discipline• Making complaints, CAPA, deviations, and risk tell one consistent story• What the investigator asks for first — and what it reveals• The QMSR-era shift: from procedures to effectiveness• The Monday-morning playbook: pull the thread before the investigator does New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • October 21 · 13 min

    Why FDA Rejects Your CAPA: 5 CAPA Effectiveness Failures Explained

    Nearly nine out of ten human-drug warning letters include at least one inadequate CAPA response. Your corrective action plan is the single most rejected document in FDA enforcement — and it's not for lack of effort. Marcus and Priya count down the five CAPA effectiveness failures that keep quality teams in warning-letter territory: fixing the event instead of the system, root causes that stop at human error, CAPAs closed with no proof they worked, CAPAs written to answer the 483 instead of fixing the system, and no trending — so the failure recurs. • Why CAPA is the most rejected document in FDA enforcement• Failure one: corrective action with no preventive action — fixing the event, not the system• Failure two: root causes that stop at "human error"• Failure three: closing a CAPA with zero evidence the change worked• Failure four: CAPAs written to answer the 483 observation, not to fix the system• Failure five: no trending — the same failure recurs, and FDA cites recurrence• The Monday-morning CAPA playbook that survives an investigator New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • October 21 · 13 min

    Why FDA Rejects Your CAPA: 5 CAPA Effectiveness Failures Explained

    Nearly nine out of ten human-drug warning letters include at least one inadequate CAPA response. Your corrective action plan is the single most rejected document in FDA enforcement — and it's not for lack of effort. Marcus and Priya count down the five CAPA effectiveness failures that keep quality teams in warning-letter territory: fixing the event instead of the system, root causes that stop at human error, CAPAs closed with no proof they worked, CAPAs written to answer the 483 instead of fixing the system, and no trending — so the failure recurs. • Why CAPA is the most rejected document in FDA enforcement• Failure one: corrective action with no preventive action — fixing the event, not the system• Failure two: root causes that stop at "human error"• Failure three: closing a CAPA with zero evidence the change worked• Failure four: CAPAs written to answer the 483 observation, not to fix the system• Failure five: no trending — the same failure recurs, and FDA cites recurrence• The Monday-morning CAPA playbook that survives an investigator New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • October 19 · 14 min

    OOS Investigation Explained: Phase 1 vs Phase 2 (21 CFR 211.192)

    An out-of-specification result lands on your desk — and one wrong decision in the next hour can manufacture the evidence for your own warning letter. Marcus and Priya break down the two-phase OOS investigation step by step: Phase 1, the laboratory investigation, and Phase 2, the full-scale investigation, under 21 CFR 211.192 — from the Barr Labs decision to the retest rules to what to do on Monday morning. • Phase 1 vs Phase 2: what each phase covers and where the line is• The retest rules — when retesting is legitimate and when it's testing into compliance• Why "no assignable lab cause" is a finding, not a failure• What 21 CFR 211.192 actually requires, in plain language• The Monday-morning OOS playbook, in five steps New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • October 14 · 14 min

    ALCOA+ Explained: The 9 Data Integrity Principles FDA Actually Cites

    When an FDA investigator stops trusting your data, the inspection is over — because if the records can't be trusted, nothing built on them can be. Marcus and Priya break down all nine ALCOA+ principles — Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available — what investigators actually find when each one is missing, and the Monday-morning fixes that close most findings before they happen. • The 9 ALCOA+ principles, explained in plain language• What investigators actually check first: audit trails, user access, backups, QA's real role• Why most data integrity 483s are discipline failures, not technology failures• The small-site objection steel-manned: where the money actually matters• The 4 moves a QA manager should make this week New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • October 12 · 13 min

    Top 10 FDA 483 Observations in 2026 (and How to Avoid Each One)

    Every year, FDA investigators write thousands of 483 observations — and almost every one was avoidable. Marcus and Priya count down the ten most-cited observations in drug manufacturing for 2026, what investigators are actually finding, and exactly how to keep your site off the list. • The #1 most-cited observation — and why it explains the other nine• Data integrity: the fastest-growing citation cluster in 2026• Why "human error + retraining" keeps failing investigations• The one quality-unit decision that changes everything New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • October 7 · 7 min

    Quality Debt: The Hidden Liability Inside Pharmaceutical Quality Systems

    Every shortcut, deferred CAPA, and "we'll fix it later" is a loan — and quality debt charges interest. Repeat deviations, findings, and warning letters are just the payments coming due. • What quality debt is and how it silently accumulates • The interest payments: repeat deviations and FDA findings • Paying it down without stopping the line • Preventing new debt while clearing the old New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one. Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161 Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • October 5 · 16 min

    The Hidden Cost of Poor Quality: The Business Impact Beyond Recalls

    Recalls make the headlines. But the real cost of poor quality never makes the press release — it hides in rework, investigations, remediation, and the launches that never happen. • The costs nobody puts on the recall announcement • Rework, investigations, and remediation: the real math • How poor quality taxes every future product launch • Making the business case for quality investment New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one. Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161 Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • September 30 · 11 min

    Why CAPA Doesn't Fix Culture: Symptoms vs Systems

    Your CAPA system can be perfect on paper and still change nothing — because CAPAs fix symptoms, and culture is the system underneath. • Why brilliant CAPAs die in broken cultures • Symptoms vs systems: knowing which one you're treating • What culture change actually requires from QA leaders • Building a system where CAPAs stick New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one. Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161 Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • September 28 · 11 min

    Compliance vs Effectiveness: Is Your Quality System Healthy?

    Compliant doesn't mean effective. Effective doesn't mean sustainable. Most quality systems are only one of the three — and leadership can't tell which. • The three lenses every quality system needs • Why compliance alone is a fragile victory • Measuring effectiveness, not just activity • Building a system that lasts beyond the next inspection New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one. Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161 Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • September 23 · 8 min

    When a Green Dashboard Lies: Signals Your Metrics Miss

    Every metric green, every trend flat — and the system is rotting underneath. Dashboards don't lie on purpose. They lie by design. • Why green metrics create dangerous comfort • The quality signals dashboards systematically miss • What to measure when the numbers look fine • Leading beyond the dashboard New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one. Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161 Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • September 21 · 19 min

    When Quality Has to Say NO: Tough QA Decisions in Pharma

    Saying no in QA is easy on paper and brutal in practice. This episode is about the decision nobody wants to make — and why making it is the job. • Why "no" is a quality decision, not a career risk • How great QA leaders frame rejection so it actually lands • The difference between blocking progress and protecting patients • Sleeping well after the hardest call of your career New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one. Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161 Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

  • September 13 · 44 min

    AI Governance in Pharma: Ethics by Design for Quality Leaders

    AI governance in the pharmaceutical industry cannot begin after deployment. By that point, critical decisions about data, accountability, human oversight, transparency, risk, and system behavior have already been embedded into the technology. So the better question is: What if ethics were designed into AI from the beginning? In this episode of The GMP Insider, we explore the concept of Ethics by Design and why it could become a foundational pillar of responsible AI governance in pharmaceutical Quality. Discussion topics include: Why AI governance must begin during system design Patient safety considerations when AI makes mistakes Transparency and understanding AI outputs Designing meaningful human oversight Data integrity and AI governance Identifying potential bias and unintended outcomes Defining accountability when AI contributes to decisions Managing AI and model changes throughout the lifecycle The evolving role of QA in AI governance Why policies alone may not be sufficient for complex AI systems For GxP and other regulated environments, responsible AI requires more than a policy describing how technology should be used. Organizations need governance principles embedded into the design, validation, deployment, monitoring, and change management lifecycle. The objective shouldn't be to create another compliance checklist. It should be to build systems with appropriate ethical guardrails from the start. Because as AI becomes more complex, governance must become more intentional. Define accountability before deployment. Design for human oversight. Protect data integrity. Monitor continuously. Engineer trust from the beginning. The central question for pharmaceutical AI should not simply be: "Can we use this technology?" It should also be: "Can we govern it responsibly—and can we trust the way it was designed?" You cannot govern complexity effectively if ethics is treated as an afterthought. From batch to patient — quality is everything.

Showing 1–20 of 46 episodes